<DOC>
	<DOCNO>NCT02385058</DOCNO>
	<brief_summary>The purpose study assess efficacy safety combination mebendazole plus quinfamide treatment intestinal helminthiasis amoebiasis Mexican population .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Double Treatment Plan Using Combination Mebendazole Quinfamide Treating Intestinal Helminthiasis Amebiasis Mexican Population</brief_title>
	<detailed_description>This double-blind ( neither investigator participant know treatment participant receives ) , placebo-controlled ( placebo inactive substance compare drug test whether drug real effect clinical trial ) , randomize ( study medication assign participant chance ) , prospective ( study follow patient forward time ) study . The total study duration participant approximately 48 day . The study consist 3 part : Screening Phase ( 5 day ) double-blind treatment Phase ( Day 1 21 , consist Phase-1 Phase-2 ) follow-up Phase ( Day 21 43 ) . Participants receive mebendazole ( 600 milligram [ mg ] ) quinfamide ( 200 mg ) tablets orally starting Day 1 mebendazole 600 mg quinfamide ( 200 mg ) placebo tablet orally start Day 21 . Efficacy primarily evaluate percentage participant eradication helminthic and/or protozoa . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Helminthiasis</mesh_term>
	<mesh_term>Amebiasis</mesh_term>
	<mesh_term>Dysentery , Amebic</mesh_term>
	<mesh_term>Mebendazole</mesh_term>
	<mesh_term>Piperazine</mesh_term>
	<mesh_term>Piperazine citrate</mesh_term>
	<criteria>Minors whose parent tutor grant his/her inform consent write participate study . Adult participant give informed consent write participate Participants coproparasitoscopy test ( scatology ) ( least 1 series 3 ) qualitative quantitative and/or search live amoeba , come positive one follow parasite : Ascaris lumbricoides , Enterobius vermicularis , Trichuris trichuria , Taenia solium , Necator americanus , Ancylostoma duodenale Trophozoites Entamoeba histolytica With least two follow symptom : Anorexia , Nausea , Vomit , Abdominal pain , Diarrhea , Constipation , Evacuations mucus , Evacuations blood , Gas discharge , Weight loss Bruxism Participants know allergy drug use investigation Female Participant reproductive age use adequate contraceptive method Pregnant lactating Participant Participant lifethreatening condition ( cancer , AIDS , etc . ) Participant know carrier illness alters metabolism drug excretion ( hepatic renal illness ) interfere absorption ( malabsorption ) interfere evaluation Participant study Participants take antiparasitic drug 14 day previous his/her inclusion clinical investigation protocol Participants diagnosis extraintestinal amoebiasis</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Helminthiasis</keyword>
	<keyword>Amoebiasis</keyword>
	<keyword>Mebendazole</keyword>
	<keyword>Quinfamide</keyword>
	<keyword>Mexican population</keyword>
</DOC>